<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02797587</url>
  </required_header>
  <id_info>
    <org_study_id>H-35288</org_study_id>
    <secondary_id>U01AA020780</secondary_id>
    <nct_id>NCT02797587</nct_id>
  </id_info>
  <brief_title>Studying Partial-agonists for Ethanol and Tobacco Elimination in Russians With HIV (St PETER HIV)</brief_title>
  <acronym>St PETER HIV</acronym>
  <official_title>URBAN ARCH 4/5 Russia Cohort-Targeting HIV-comorbidities With Pharmacotherapy to Reduce Alcohol and Tobacco Use in HIV-infected Russians</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Alcohol Abuse and Alcoholism (NIAAA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Boston Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a randomized controlled trial (RCT) to compare the effects of varenicline,&#xD;
      cytisine, and nicotine replacement therapy (NRT) to reduce: 1) alcohol use and craving, 2)&#xD;
      smoking; and 3) inflammation and risk for coronary heart disease (CHD) and mortality among&#xD;
      400 HIV-infected Russians, with heavy alcohol consumption and tobacco use.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      HIV-infected heavy drinking smokers are at high risk for coronary heart disease (CHD) and&#xD;
      death. The mechanisms driving increased CHD risk in HIV-infected people are unclear, but are&#xD;
      linked to inflammation. HIV, heavy drinking, and smoking are all pro-inflammatory. HIV viral&#xD;
      suppression with antiretroviral therapy does not eliminate the elevated CHD risk nor the&#xD;
      increased inflammation (i.e., pre-HIV infection levels are not restored). Interventions that&#xD;
      reduce alcohol use, smoking, or both in HIV-infected people could lower inflammation, CHD and&#xD;
      death risk. Varenicline and cytisine are proven therapies for smoking cessation. When&#xD;
      compared to placebo, varenicline has higher cessation rates than cytisine. Human trials&#xD;
      suggest varenicline also has efficacy for reducing alcohol consumption and craving in heavy&#xD;
      drinking smokers. In murine models, cytisine reduces alcohol consumption. The comparative&#xD;
      efficacy of varenicline and cytisine to reduce alcohol consumption and by extension,&#xD;
      inflammation, CHD, and mortality risk, in humans has not been tested, nor has their&#xD;
      comparative effectiveness been tested for smoking. Neither drug has been tested for smoking&#xD;
      cessation against nicotine replacement therapy (NRT) in HIV-infected heavy drinking smokers.&#xD;
      Three compelling reasons to test varenicline and cytisine in HIV-infected heavy drinking&#xD;
      smokers are: 1) both show promise in HIV-uninfected people; 2) the morbidity caused by heavy&#xD;
      drinking and smoking in HIV-infected persons is significant; and 3) treating heavy drinking&#xD;
      and smoking with one medication represents a significant advance in reducing polypharmacy and&#xD;
      improving patient care. Thus, investigators propose a 4-arm placebo-controlled randomized&#xD;
      controlled trial (RCT) among 400 HIV-infected heavy drinking smokers. Trial arms are&#xD;
      varenicline+NRT placebo, cytisine+NRT placebo, NRT+varenicline placebo, NRT+cytisine placebo.&#xD;
      All participants will receive counseling (alcohol &amp; tobacco) and medications (placebo &amp;&#xD;
      active). Specific aims will compare effects of varenicline, cytisine, and NRT at 3 months on&#xD;
      past month % heavy drinking days and alcohol craving, cigarettes per day and smoking&#xD;
      abstinence (verified by carbon monoxide), inflammation (hsCRP, IL-6), CHD (Reynolds risk&#xD;
      score), and mortality (VACS index) risk. Investigators hypothesize that (1) Varenicline has&#xD;
      greater efficacy than NRT for reducing heavy drinking, smoking, inflammation, CHD and&#xD;
      mortality risk; (2) Cytisine has greater efficacy than NRT; and (3) Varenicline has greater&#xD;
      efficacy than cytisine for these outcomes. Investigators will conduct an RCT, Studying&#xD;
      Partial-agonists for Ethanol and Tobacco Elimination in Russians with HIV (St PETER HIV), in&#xD;
      a country with an HIV epidemic and high per-capita alcohol consumption and smoking.&#xD;
      Investigators will recruit from the ongoing Russia ARCH cohort in St. Petersburg (part of our&#xD;
      NIAAA funded HIV/AIDS Alcohol Consortium - URBAN ARCH). If investigator hypotheses are&#xD;
      correct, St PETER HIV could make nicotinic partial-agonists standard care for HIV+ heavy&#xD;
      drinking smokers, and lead to reduced inflammation, CHD and mortality risk through this &quot;one&#xD;
      drug, two diseases&quot; approach. This trial addresses the paucity of RCT data to guide treatment&#xD;
      of these CHD risk factors in HIV-infected people.&#xD;
&#xD;
      The Russia ARCH Cohort and the St PETER HIV study will draw from an established cohort of&#xD;
      HIV-infected smokers and heavy drinkers to compare the effects of two partial nicotinic&#xD;
      receptors, varenicline and cytisine, on alcohol consumption, alcohol craving, smoking,&#xD;
      inflammation, CHD risk and mortality risk. St PETER HIV further addresses the paucity of&#xD;
      randomized controlled trial data to guide treatment of heavy alcohol consumption and smoking&#xD;
      in HIV-infected people.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 19, 2017</start_date>
  <completion_date type="Actual">December 15, 2020</completion_date>
  <primary_completion_date type="Actual">April 30, 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent heavy drinking days in past 30 days</measure>
    <time_frame>Participants will be followed for up to 12 months (primary endpoint at 3 month)</time_frame>
    <description>Self-reported past 30-day alcohol consumption obtained via the Timeline Followback (TLFB) method, heavy drinking defined by NIAAA definition</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Alcohol craving</measure>
    <time_frame>Participants will be followed for up to 12 months (primary endpoint at 3 month)</time_frame>
    <description>Measured by the Penn Alcohol Craving Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Carbon monoxide-validated smoking cessation</measure>
    <time_frame>Participants will be followed for up to 12 months (primary endpoint at 3 month)</time_frame>
    <description>Self-reported 7-day point prevalence abstinence and a carbon monoxide measured in end-expired air threshold of &lt;10 ppm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coronary heart disease risk</measure>
    <time_frame>Participants will be followed for up to 12 months (primary endpoint at 3 month)</time_frame>
    <description>Measured by the Reynolds risk score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality risk</measure>
    <time_frame>Participants will be followed for up to 12 months (primary endpoint at 3 month)</time_frame>
    <description>Measured by the VACS index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cigarettes per day in past 7 days</measure>
    <time_frame>Participants will be followed for up to 12 months (primary endpoint at 3 month)</time_frame>
    <description>Self-report, obtained via Timeline Followback (TLFB) method</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hsCRP levels</measure>
    <time_frame>Participants will be followed for up to 12 months (primary endpoint at 3 month)</time_frame>
    <description>Biomarker of inflammation measured via study test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IL-6 levels</measure>
    <time_frame>Participants will be followed for up to 12 months (primary endpoint at 3 month)</time_frame>
    <description>Biomarker of inflammation measured via study test</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">400</enrollment>
  <condition>HIV Infection</condition>
  <condition>Alcohol Use</condition>
  <condition>Smoking</condition>
  <arm_group>
    <arm_group_label>Varenicline + Nicotine Replacement Therapy placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Study participants will receive active varenicline and be instructed to take the medication for 12 weeks; participants will also receive a placebo Nicotine Replacement Therapy mouth spray for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Varenicline placebo + Nicotine Replacement Therapy</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Study participants will receive placebo varenicline and be instructed to take the placebo medication for 12 weeks; participants will also receive an active Nicotine Replacement Therapy mouth spray for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cytisine + Nicotine Replacement Therapy placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Study participants will receive active cytisine and be instructed to take the medication for 25 days; participants will also receive a placebo Nicotine Replacement Therapy mouth spray for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cytisine placebo + Nicotine Replacement Therapy</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Study participants will receive placebo cytisine and be instructed to take the medication for 25 days; participants will also receive an active Nicotine Replacement Therapy mouth spray for 8 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Varenicline</intervention_name>
    <description>1 week starter kit followed by 1mg twice daily for 12 weeks.</description>
    <arm_group_label>Varenicline + Nicotine Replacement Therapy placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytisine</intervention_name>
    <description>Multi-daily dosing, range 3-9 mg daily for 25 days.</description>
    <arm_group_label>Cytisine + Nicotine Replacement Therapy placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nicotine Replacement Therapy</intervention_name>
    <description>Mouth spray dosing based on standard recommendations tapered over 8 weeks.</description>
    <arm_group_label>Cytisine placebo + Nicotine Replacement Therapy</arm_group_label>
    <arm_group_label>Varenicline placebo + Nicotine Replacement Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Varenicline Placebo</intervention_name>
    <description>1 week starter kit followed by 1 pill twice daily for 12 weeks.</description>
    <arm_group_label>Varenicline placebo + Nicotine Replacement Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytisine Placebo</intervention_name>
    <description>Multi-daily dosing for 25 days.</description>
    <arm_group_label>Cytisine placebo + Nicotine Replacement Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nicotine Replacement Therapy Placebo</intervention_name>
    <description>Mouth spray dosing based on standard recommendations tapered over 8 weeks.</description>
    <arm_group_label>Cytisine + Nicotine Replacement Therapy placebo</arm_group_label>
    <arm_group_label>Varenicline + Nicotine Replacement Therapy placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18-70 years old&#xD;
&#xD;
          -  HIV-infected&#xD;
&#xD;
          -  â‰¥ 5 heavy drinking days in the past 30 days (NIAAA at-risk drinking levels)&#xD;
&#xD;
          -  Smoking an average of at least 5 cigarettes per day&#xD;
&#xD;
          -  Provision of contact information for 2 contacts to assist with follow-up&#xD;
&#xD;
          -  Stable address within 100 kilometers&#xD;
&#xD;
          -  Possession of a telephone (home or cell)&#xD;
&#xD;
          -  Interest in cutting down/quitting alcohol or tobacco&#xD;
&#xD;
          -  Able and willing to comply with all study protocols and procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Not fluent in Russian&#xD;
&#xD;
          -  Cognitive impairment&#xD;
&#xD;
          -  Pregnant or planning to become pregnant in next 3 months&#xD;
&#xD;
          -  Breastfeeding&#xD;
&#xD;
          -  Unstable psychiatric illness (i.e. ,answered yes to any of the following: past three&#xD;
             month a) active hallucinations; b) mental health symptoms prompting a visit to the ED&#xD;
             or hospital; mental health medication changes due to worsening symptoms; presence of&#xD;
             suicidal ideations)&#xD;
&#xD;
          -  History of pheochromocytoma&#xD;
&#xD;
          -  Taking smoking cessation medications in past 30 days&#xD;
&#xD;
          -  History of seizures&#xD;
&#xD;
          -  History of Buerger's disease&#xD;
&#xD;
          -  Acute coronary syndrome within 1 month of enrollment&#xD;
&#xD;
          -  Systolic BP &gt; 180 mm Hg or diastolic BP &gt; 105 mm Hg&#xD;
&#xD;
          -  Currently taking anti-tuberculosis medications&#xD;
&#xD;
          -  Currently taking Galantamine or Physostigmine&#xD;
&#xD;
          -  BAC level of 0.10% or higher&#xD;
&#xD;
          -  Known allergy to varenicline (Chantix) or cytisine (Tabex)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey H Samet, MA, MA, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Boston University/Boston Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>First St. Petersburg Pavlov State Medical University</name>
      <address>
        <city>St. Petersburg</city>
        <zip>197022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <link>
    <url>http://www.urbanarch.org</url>
    <description>URBAN ARCH, a member of NIAAA CHAART (Consortiums for HIV/AIDS &amp; Alcohol Research Translation) initiative, conducts and disseminates interdisciplinary research on how alcohol impacts people with HIV and develops interventions to reduce related outcomes.</description>
  </link>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>June 8, 2016</study_first_submitted>
  <study_first_submitted_qc>June 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 13, 2016</study_first_posted>
  <last_update_submitted>December 16, 2020</last_update_submitted>
  <last_update_submitted_qc>December 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Boston Medical Center</investigator_affiliation>
    <investigator_full_name>Jeffrey Samet</investigator_full_name>
    <investigator_title>Chief, Section of General and Internal Medicine</investigator_title>
  </responsible_party>
  <keyword>Alcohol Use</keyword>
  <keyword>Tobacco Use</keyword>
  <keyword>Smoking</keyword>
  <keyword>Inflammation</keyword>
  <keyword>Coronary Heart Disease</keyword>
  <keyword>Russia</keyword>
  <keyword>Varenicline</keyword>
  <keyword>Cytisine</keyword>
  <keyword>Nicotine Replacement Therapy</keyword>
  <keyword>Partial Agonist Therapy</keyword>
  <keyword>HIV</keyword>
  <keyword>Reynolds risk score</keyword>
  <keyword>VACS index</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alcohol Drinking</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
    <mesh_term>Varenicline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All data from the study will be placed into the URBAN ARCH repository.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

